"Rosuvastatin Calcium" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A HYDROXYMETHYLGLUTARYL-COA-REDUCTASE INHIBITOR, or statin, that reduces the plasma concentrations of LDL-CHOLESTEROL; APOLIPOPROTEIN B, and TRIGLYCERIDES while increasing HDL-CHOLESTEROL levels in patients with HYPERCHOLESTEROLEMIA and those at risk for CARDIOVASCULAR DISEASES.
| Descriptor ID |
D000068718
|
| MeSH Number(s) |
D02.065.884.650 D02.455.526.510.432.500 D02.886.590.700.650 D03.383.742.775
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rosuvastatin Calcium".
Below are MeSH descriptors whose meaning is more specific than "Rosuvastatin Calcium".
This graph shows the total number of publications written about "Rosuvastatin Calcium" by people in this website by year, and whether "Rosuvastatin Calcium" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 6 | 6 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 5 | 5 |
| 2014 | 0 | 4 | 4 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rosuvastatin Calcium" by people in Profiles.
-
Attainment of low-density lipoprotein cholesterol goals in patients undergoing coronary revascularization in the contemporary clinical practice. Indian Heart J. 2024 Nov-Dec; 76(6):414-417.
-
Controlled Delivery of Rosuvastatin or Rapamycin through Electrospun Bismuth Nanoparticle-Infused Perivascular Wraps Promotes Arteriovenous Fistula Maturation. ACS Appl Mater Interfaces. 2024 Jul 03; 16(26):33159-33168.
-
Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD? J Fam Pract. 2023 06; 72(5):227-229.
-
Technology-Assisted Self-Selection of Candidates for Nonprescription Statin?Therapy. J Am Coll Cardiol. 2021 09 14; 78(11):1114-1123.
-
Classic and targeted anti-leukaemic agents interfere with the cholesterol biogenesis metagene in acute myeloid leukaemia: Therapeutic implications. J Cell Mol Med. 2020 07; 24(13):7378-7392.
-
Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery. J Pharm Biomed Anal. 2019 Feb 05; 164:258-267.
-
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
-
Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice. Cardiovasc Drugs Ther. 2017 Dec; 31(5-6):489-500.
-
Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. Atherosclerosis. 2017 Aug; 263:137-144.
-
Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine. Cardiovasc Drugs Ther. 2016 Dec; 30(6):539-550.